Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
CMPI was delisted on the 27th of May, 2022.
31 hedge funds and large institutions have $64.5M invested in Checkmate Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less funds holding
Funds holding: 34 → 31 (-3)
34% less capital invested
Capital invested by funds: $97.3M → $64.5M (-$32.8M)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$437K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$188K |
| 3 |
BlackRock
New York
|
+$149K |
| 4 |
State Street
Boston,
Massachusetts
|
+$57.1K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$19.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$803K |
| 2 |
Millennium Management
New York
|
-$241K |
| 3 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
-$149K |
| 4 |
Renaissance Technologies
New York
|
-$66K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$46K |
CMPI Hedge Fund Activity: Q3 2021 in Review
31 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) for Q3 2021, worth a combined $64.5M — down 34% from $97.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CMPI and 3 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $437K. The largest seller was Deutsche Bank, exiting entirely with an estimated $803K sold.
- 31 institutional investors held Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) as of Q3 2021, down from 34 in Q2 2021.
- Funds reported $64.5M of Checkmate Pharmaceuticals, Inc. Common Stock stock for Q3 2021, down 34% quarter-over-quarter.
- 3 funds opened new Checkmate Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 6 closed out, a net change of -3 holders.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Bridgeway Capital Management, an estimated $437K added.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was Deutsche Bank, an estimated $803K sold.
Based on aggregated 13F filings for Q3 2021.